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Prednisolone is a synthetic corticosteroid acting on both hydrosaline balance and metabolism that is liable to fraudulent administration to 
meat-producing animals for growth-promoting purposes. Its use outside strict therapeutic control and prescription is banned by the 
European legislation, but official controls are hampered by its negligible direct excretion into the urinary matrix. Recent studies reported 
on a potential endogenous origin of prednisolone in animals subjected to stressful conditions, accounting for its occasional detection in 
control urines. The objective of the present study was the identification and quantification of prednisolone urinary metabolites to be used as 
illicit treatment biomarkers in place of the parent drug. An LC-MS/MS screening was conducted on urine samples collected from a bullock 
intramuscularly administered with prednisolone acetate by using a therapeutic protocol (2 x 0.52 mg kg l at 48-hour interval). Four 
prednisolone metabolites were identified: 20β-dihydroprednisolone, 20α-dihydroprednisolone, 6β-hydroxyprednisolone and 
20β-dihy-droprednisone; the first was detected at relatively high concentrations. An existing quantitative LC-MS/MS method was 
expanded and revalidated to include these metabolites. The new analytical method proved sensitive (LODs: 0.35-0.42 ng mL l) 
and specific and was applied to urine samples collected from eight beef cattle subjected to low-dosage oral administration of prednisolone 
acetate for a 35-day period, as in standard growth-promoting treatments. 20β-Dihydroprednisolone was detected in all urine samples 
collected during the treatment, at relatively high concentration (1.2-27 ng mL-1), whereas the prednisolone concentration was 
virtually negligible (<0.7 ng mL -1). 20β-Dihydroprednisolone was no longer present in almost all samples collected 6 days after the 
end of the treatment, but trace amounts of this metabolite were found in two urine samples from control animals. 
20β-Dihydroprednisolone is proposed as an effective biomarker to test illegal growth-promoting treatments with prednisolone in meat 
cattle, alternatively to the parent drug. 
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Introduction 
Natural corticosteroids are synthesised by the adrenal cortex and include two families of substances: mineralocorti-coids and 
glucocorticoids. Mineralocorticoids influence the electrolyte-water balance, while glucocorticoids act on carbohydrate 
and protein metabolism (Savu et al. 1996; Courtheyn et al. 2002). Glucocorticoids are known to be very potent 
anti-inflammatory drugs. Their pharmacological properties led to the synthesis of new molecules with similar structure and 
enhanced activity, which are extensively used in both human and veterinary clinical practice (Antignac et al. 2001; Deventer 
& Delbeke 2003). In recent years, a number of synthetic glucocorticoids have been illegally used at very low doses mainly 
by the oral route to improve the zootechnical performance in meat cattle (Courtheyn et al. 2002; Nebbia et al. 2010). The 
strong pharmacological activity of most synthetic glucocorticoids used in animal breeding makes the residues of these 
molecules potentially dangerous for meat and milk consumers. As a consequence, their administration for 
growth-promoting purposes is strictly banned in the European Union  (Stolker &  Brinkman 2005;  De Brabander et 
al. 2007). 
Prednisolone is among the most frequently detected synthetic glucocorticoids in bovine urine samples during Regione Piemonte 
(Italy) official controls (Leporati et al. 2012). Unlike other analogues, such as dexamethasone, prednisolone does not contain any 
halogen atom and its structure closely resembles that of other endogenous steroids, including cortisol. From this structural 
similarity arises the hypothesis that in meat cattle prednisolone could be generated by physiological metabolic processes, possibly 
under extremely stressful conditions, such as transport and slaughtering, or by faecal contamination, as is supported by a few recent 
studies (Arioli et al. 2010; Ferranti et al. 2011; Pompa et al. 2011). On the basis of these results and the opinion of the European Union 
Reference Laboratory, the Italian Ministry of Health has recently enacted a new disposition: a bovine urine sample is considered 
non-compliant for prednisolone only when its concentration exceeds 5.0 ng mL 
l
 (Circular of Ministry of Health 2012). 
However, we recently published a study demonstrating that the urine of beef cattle treated with low doses of prednisolone acetate 
for extended periods of time, as occurs in growth-promoting illegal treatments, may contain prednisolone at 1 ng rnlT
1
 or even 
below. So far, the metabolic fate of the administered prednisolone acetate is relatively unknown and new approaches including 
metabolic studies are required to discriminate between exogenous and endogenous prednisolone origin, so as to clearly detect 
any illicit treatment (Blokland et al. 2007; Pinel et al. 2008; Destrez et al. 2009). The rapid conversion of prednisolone to 
prednisone is known to occur in cattle (EMEA 1999) as a result of the 11 β-hydro-xysteroid dehydrogenase-mediated oxidation 
of the -OH group at C11 (Divari et al. 2011). No further recent study is available concerning prednisolone metabolism in cattle, 
whereas many metabolic studies are reported in humans, starting more than 50 years ago. Vermeulen and Caspi (1959) isolated 
20α-dihydroprednisolone, 20β-dihydropredni-solone and 20β-dihydroprednisone in the urines of leukaemic patients treated with 
prednisolone (see Figure 1). 
 The formation of the latter metabolites and 6β-hydroxypredniso-lone was also studied by Gray et al. (1956) and Garg and 
Jusko (1991). 
Generally, the oxidative metabolism, catalysed by cytochrome P450 (-CH>-OH), is considered more important than 
the reductive one (-C = O> -CH-OH), although the latter represents a significant step of steroid hormones phase I 
biotransformation. The conversion of prednisolone in 20α- and 20β-dihydroprednisolone in man is catalysed by two 
hydroxysteroid dehydrogenases, namely, 20α-hydroxysteroid dehydrogenase and 3α,20β-hydroxysteroid dehydrogenase 
(Maser 1995). A scheme of the principal prednisolone metabolites is reported in Figure 1. 
In the present study, we reanalysed the urines of beef cattle experimentally treated with low dosages of prednisolone 
acetate according to a growth-promoting schedule, previously displaying levels of the parent drug either  negligible or 
close to the detection limit, even when a sensitive LC-MS/MS confirmation method was used (Cannizzo et al. 2011; 
Vincenti et al. 2012). The main objective of our study was to verify the possible presence of prednisolone metabolites, which 
could justify the rapid disappearance of the parent drug and provide evidence of the low-dosage illicit-simulating treatment 
administered to the animals. To obtain clear evidence of the possible metabolites formed by prednisolone biotransformation 
in bovines, our work started with the analysis of the urines of a bullock treated with prednisolone acetate using a therapeutic 
protocol involving much higher drug dosages compared with the growth-promoting one. 
 
Figure 1.    Hypothetical biotransformation pathways of prednisolone. CYP 450, cytochrome P450; HSD, hydroxysteroid dehydrogenase; 
MW, molecular weight. 
Materials and methods 
Urine sampling from a bullock pharmacologically treated with prednisolone acetate 
A Charolais bullock was treated twice with prednisolone acetate (0.52 mg kg
-1
 intramuscularly at 2-day interval). Urine 
samples were collected before the treatment and 10 days after the first administration. 
Urine sampling from beef cattle treated with low dosages of prednisolone acetate 
Animal treatment and experimental design were described in a previous study (Cannizzo et al. 2011). We decided to 
re-analyse all the urine samples from group D animals (eight Friesian beef cattle, male, 10-17 months old, orally 
administered with prednisolone acetate 30 mg day
-1
 for 35 days) and the samples collected from two untreated animals 
(group K negative controls). Urine was collected at days 0, 10, 31 and 41 in early morning after spontaneous micturition by 
licensed veterinarians, taking care to prevent faecal contamination. The samples were divided into aliquots and stored at 
-80°C until the analysis was performed. The last sampling was carried out at the slaughterhouse. These samples were 
analysed once in 2010, and the results were published in Cannizzo et al. (2011). They were re-analysed in 2012, to detect the 
prednisolone metabolites. The stability of the prednisolone was evaluated by comparing the quantitative results: the repeated 
analysis of urine samples provided strictly comparable concentrations for prednisolone, as obtained in the previous study 
conducted on fresh aliquots. 
Chemicals, reagents and standard solutions 
Diethylether and acetonitrile were supplied by Sigma-Aldrich (St. Louis, MO, USA). Sodium hydroxide and hydrochloric acid 
were purchased from Carlo Erba Reagenti (Milan, Italy). Betaglucuronidase/aryl-sulfatase was from Roche Diagnostics    
(Mannheim, Germany). 20α-Dihydroprednisolone, 20β-dihydroprednisolone, 6β-hydroxyprednisolone and 
20β-dihydroprednisone were supplied by Steraloids (Newport, RI, USA). Triamcinolone acetonide-d6 (internal standard (IS)) 
was from RIVM (Bilthoven, The Netherlands). Stock standard solutions of 20α-dihydroprednisolone, 20β-dihydro-prednisolone, 
6β-hydroxyprednisolone and 20β-dihydropred-nisone were prepared in acetonitrile at a concentration of 1 mg I/1 and stored 
at -20°C in the dark. 
Sample preparation and instrumental analysis 
Sample preparation and instrumental analysis were conducted as reported in Vincenti et al. (2012). Briefly, urine samples 
were subjected to a liquid/liquid extraction at pH 8.5-9.5 with diethylether after β-glucuronidase/aryl-sulfatase 
deconjugation. After centrifugation, the supernatant organic phase was transferred into a 10-mL glass tube and evaporated to 
dryness under nitrogen by heating at 40°C. The residue was re-dissolved in 50 μL of H2O/ CH3CN (70/30) solution and 
transferred into analytical vials for analysis. Instrumental analysis was performed by LC-MS/MS using the 
chromatographic conditions previously described (Cannizzo et al. 2011). The LC was interfaced to an Applied Biosystems 
API 4000 triple-quadrupole mass spectrometer (Applied Biosystems Sciex, Ontario, Canada), operating in atmospheric 
pressure chemical ionisation positive ion mode. 
Mass spectrometric conditions for qualitative and quantitative analysis 
The qualitative search for prednisolone metabolites was conducted on the urine samples collected from the bullock treated 
with prednisolone acetate using a therapeutic schedule. The tandem mass spectrometer was operated in the product ion scan 
mode, that is, the protonated molecular ions of hypothetical prednisolone metabolites were selected with the first 
quadrupole (Q1), then fragmented in the intermediate cell upon collision with nitrogen molecules (Q2) and finally the 
product ions were analysed by the third quadrupole (Q3) under continuous scanning conditions. 
Quantitative analyses were performed in the SRM mode by using three SRM transitions for each analyte, and the 
experimental conditions are reported in Table 1. 
Method validation 
The analytical method was originally developed and fully validated for prednisolone and prednisone according to Commission 
Decision 2002/657/EC. The validation procedure is described in a previous study (Cannizzo et al. 2011), reporting CCα values of 0.67 
and 0.66 ng rnL
-1
, respectively. A simplified validation was executed on the present analytical method, which was modified to include 
20β-dihydroprednisolone, dihydroprednisolone, 6β-hydroxyprednisolone and 20β-dihy-droprednisone. Specificity, linearity, LOD, 
LOQ, precision (in terms of intra-laboratory repeatability), accuracy and trueness were estimated for these metabolites. 
 
Table 1.    Mass spectrometric acquisition parameters for SRM operating mode. 
Note: Q, Quantifier transition. 
 
.Identification criteria and specificity 
Identification criteria for the analytes were established according to international guidelines (European Commission 
2002). Three SRM transitions were considered for each analyte. Variations in relative SRM transition intensities were judged 
compliant with respect to the corresponding standard within a ±20% error. Ten different blank urine samples were analysed. The 
occurrence of possible interferences from endogenous substances was tested by monitoring the SRM profiles characteristic for 
each investigated compound at the retention time interval expected for their elution. A signal-to-noise ratio of <3 was 
considered satisfactory to verify the method specificity. 
Linearity 
The linear calibration model was checked by analysing (three replicates) blank urine samples spiked with standard solutions 
at six final concentrations (0, 1, 2 3, 5 and 10 ng mL 
l
). Linearity fit was roughly verified by using squared correlation 
coefficients (R
2
). 
LOD and LOQ 
The LOD was calculated by extrapolation from the three lowest non-zero levels, as the concentration of the analyte that gives 
a signal (peak height) equal to the average background of the blank (Sblank) plus three times its standard deviation (LOD 
= Sblank + 3Sblank ). LOQ values were verified experimentally as the first non-zero level of the calibration curves for each 
analyte 
 
 
Precision, accuracy and trueness 
Precision (in terms of intra-laboratory repeatability), accuracy and trueness were estimated as a percentage of the theoretic 
value, by quantifying the analytes using the Internal Standard (IS) correction factor. Five replicates at three concentration 
levels (1, 3 and 10 ng mL 
h
) were averaged for trueness evaluation. 
Results and discussion 
Qualitative analysis of urine samples 
The qualitative exploration of potential prednisolone metabolites was carried out on the urine samples collected from a 
bullock treated twice with dosages of prednisolone acetate higher than those used for growth-promoting purposes, following 
standardised conditions for pharmacological treatments. Under these conditions, it was expected that the hypothetical 
metabolites could be found in urine at higher concentrations than after a long-term low-dosage treatment. 
Using a standard chromatographic run, the tandem mass spectrometer was programmed so as the first quad-rupole (Q1) 
sequentially selected the protonated molecular ions of the potential metabolites depicted in Figure 1, while the second 
quadrupole (Q3) was operated in the continuous scanning mode to collect the corresponding product ion spectra. Following 
this procedure, the most interesting results were observed from the product ion 
 spectra obtained after the isolation of m/z 363.5 on Q1. Figure 2(A) reports the comparison of the m/z 363.5 chromatographic 
profiles obtained from the urines collected before the treatment and 10 days after the first administration, respectively. A high 
chromatographic peak is evident at the retention time of 11.26 minutes only in the profile from the urine collected after the 
treatment. The corresponding product ion spectrum, depicted in Figure 2(B), exhibits the consecutive losses of four water 
molecules from the protonated molecular ion, which are compatible with the structure of both 20α-dihydroprednisolone and 
20β-dihydroprednisolone, that is, two metabolites already found in the studies conducted on humans (Vermeulen & Caspi 
1959). 
Confirmation that the chromatographic peak detected at a retention time of 11.26 minutes could be attributed to 
20β-dihydroprednisolone was obtained by the analysis of a 20β-dihydroprednisolone analytical standard solution at a 
concentration of 10 μg mL_1. Identical retention time (Figure 2C) and product ion spectrum (Figure 2D), within the random 
experimental error, were observed from the pure standard with respect to the real urine sample. To exclude possible 
co-elution and interference from the 20α-dihydroprednisolone isomer, the latter was also analysed as a pure analytical 
standard solution at 10 μg mL_1 concentration. The results are reported in Figure 2(E) and (F), showing similar product ion 
spectrum, but significantly different retention time with respect to the 20β-isomer, as expected. It is also evident that the 
chromatographic separation between the two isomers is so large that easy recognition of the two potential metabolites is 
possible, but 20α-dihydroprednisolone could not be detected in these preliminary experiments. Likewise, neither 
6β-hydroxyprednisolone nor 20β-dihydropredni-sone could be picked out from product ion scanning experiments, possibly 
because of the limited sensitivity of the technique. Thus, the analysis on the same urine samples was repeated using the 
SRM mode of operation, to increase the sensitivity, after appropriate method validation. 
 
Validation of the quantitative analytical method 
An overview of the results obtained for analytical method validation is given in Table 2. 
Specificity 
The SRM chromatographic profiles obtained from 10 blank matrix samples did not show the presence of any significant 
signal (S/N < 3) at the relative retention time typical of the studied compounds, indicating that the method is specific, and 
no interfering substance is present in the biological matrice. 
Linearity 
Calibration curves were linear in the range 1-10 ng mL
_1
. The calibration fit showed squared correlation coefficients (R
2
) of 
0.9973, 0.9980, 0.9973 and 0.9949 for 20β-dihy-droprednisolone, 20α-dihydroprednisolone, 6β-hydroxy-prednisolone and 
20β-dihydroprednisone, respectively. 
LOD and LOQ 
LOD values, obtained by extrapolation from the first three levels of the calibration curves, ranged between 0.35 and 0.42 ng 
mL \ These values are very similar to one another and demonstrated that the sensitivity of the method for structurally 
similar substances is quite homogeneous. Therefore, LOQ values were also consistently verified at 1 ng mL
-1
 for all 
analytes, making it possible to experimentally test precision, accuracy and trueness at the same LOQ value. 
Precision, accuracy and trueness 
Precision (as within-laboratory repeatability) was expressed by the variation coefficient from five replicated samples: it 
ranged between 2% and 8%. Accuracy was satisfactory for all analytes, as it showed a maximum error of ±13%, and proved 
not to depend on their concentration. Trueness ranged from 96% to 108% of the expected value, confirming the 
appropriateness of the present method for quantitative determinations. 
Analysis of urine samples from high- and low-dosage-treated animals 
The urine samples used for qualitative analysis were re-analysed by using the SRM mode of operation. The increased 
sensitivity allowed by the SRM technique is expressed in Figure 3, showing the chromatographic profiles of the three SRM 
transitions specifically selected to highlight the possible presence of 20α-dihydropredniso-lone. Alongside the out-of-scale 
peak found at about 11.20 minutes, owing to the 20β-isomer, a new peak appeared in all profiles at the retention time of 
10.32 minutes, matching that of the 20β-dihydroprednisolone pure standard. Likewise, the chromatographic profiles of the 
six SRM transitions that selectively monitored the presence of 6β-hydroxyprednisolone and 20β-dihydro-prednisone (three 
SRM transitions each) showed coincident peaks for the real urine sample and pure standard solutions of the same 
substances (Figure 4). This demonstrated that 20β-dihydroprednisolone, 20α-dihydro-prednisolone, 6β-hydroxyprednisolone 
and 20β-dihydro-prednisone are all bovine metabolites of prednisolone, but the first compound is produced to a much 
greater extent than the other metabolites. 
 
Figure 2. (A) Superimposed mass chromatograms of the m/z 363.3 precursor ion, obtained from the urine samples of a pharmacolo-
gically treated bullock, collected before the treatment (dotted line) and 10 days after the first treatment (continuous line). (B) Product ion 
spectrum of the selected m/z 363.3 precursor, collected at 11.26 minutes, from the latter analysis. (C) Mass chromatogram of the m/z 363.3 
precursor ion, obtained from a 10 μg mL-1 solution of 20β-dihydroprednisolone. (D) Product ion spectrum of the selected m/z 363.3 
precursor, collected at 11.26 minutes, from the 10 μg mL l 20β-dihydroprednisolone standard solution. (E) Mass chromatogram of the m/z 
363.3 precursor ion, obtained from a 10 μg mL~ solution of 20α-dihydroprednisolone. (F) Product ion spectrum of the selected m/z 363.3 
precursor, collected at 10.32 minutes, from the 10 μg mL l 20α-dihydroprednisolone standard solution. CE, collision energy. 
Table 2.    Validation results. 
 
 
The subsequent step of our work was to explore the possible presence of the same metabolites in the trial urine samples of 
beef cattle treated with a low dosage (30 mg day
1
) of prednisolone acetate for an extended period of time. In our previous 
work (Cannizzo et al. 2011), we found that the extremely low concentration of prednisolone detected in the urine samples 
contributed only to a negligible extent to the overall drug excretion. Even the expected partial interconversion of prednisolone 
to prednisone could not compensate for the missing parent drug, but no other metabolites could be put forward at that time. 
The extended analytical protocol for metabolites' monitoring developed in the present study was applied to the urine 
samples collected from a group of eight treated beef cattle (identified as group D, in the preceding study) plus two untreated 
animals, used as negative controls. Among the target metabolites, none of the minor ones (i.e., 20α-dihydroprednisolone, 
6β-hydroxyprednisolone and   20β-dihydroprednisone) could be detected.  In contrast, the major prednisolone metabolite, 
namely, dihydroprednisolone, was also found in these urine samples, at concentrations largely exceeding the residual parent 
drug content. 
The sensitivity of the analytical method towards the target metabolites can be appreciated from the left side of Figure 5, 
which presents the SRM chromatographic profiles characteristic for 20β-dihydroprednisolone and obtained from a blank 
urine sample spiked with 20α-and 20β-dihydroprednisolone at the final concentration of 1 ng mL '. Much larger 
concentrations of 20β-dihydro-prednisolone are observed in the urine samples of the treated animal, as is evident from the 
SRM chromatographic profiles obtained from the urine sample collected at the 10th day of treatment from the animal 
identified as 28 D (Figure 5, central column). However, trace amounts of 20β-dihydroprednisolone were also occasionally 
detected in the urine samples collected from control animals, as is shown on the right side of Figure 5.  
 
 Figure 3.    Chromatographic profiles of the three SRM transitions distinctive for 20α-dihydroprednisolone from the urine sample 
collected 10 days after the first pharmacological administration of prednisolone acetate to a bullock. 
It should be noted that control animals were breeded under strictly controlled conditions and exogenous contribution can be 
excluded. However, this result has to be confirmed on a larger set of samples and animals by using a dedicated analytical 
method. If confirmed, the estimation of a threshold value for 20β-dihydroprednisolone concentration in the urine of 
untreated animals will provide sure discrimination between treated and untreated animals. 
The quantitative results obtained from the urine of treated and untreated beef and analysed in duplicate are reported in 
Table 3. Taking into account that the low-dosage treatment with prednisolone acetate lasted 35 consecutive days, the most 
striking result deduced from Table 3 is that the urine of treated beef cattle showed virtually no presence of prednisolone even 
during the treatment, whereas its main metabolite, namely, 20β-dihydropredni-solone, was detected at relatively high 
concentrations (up to 27 ng mL 
l
) in all treated animals. Another notable observation is that the urine samples of almost all 
treated beef cattle became negative to both 20β-dihydropredniso-lone and its precursor just 6 days after the end of the 
treatment. For comparison, low but measurable urinary levels (0.5-1.5 ng mL 
l
) of either prednisolone or prednisone were 
found 31 days after the second administration in bullocks and cows subjected to the same pharmacological protocol 
described in the bullock from this study (Nebbia et al. unpublished results). The only positive sample at day 41 was 
observed for animal 31 D (1.9 ng mL 
l
), also presenting a metabolite peak delayed (maximum at day 31) with respect to 
other animals (with a concentration of almost 21 ng mL 
l
). 
Conclusions 
The identification of 20β-dihydroprednisolone as a major prednisolone metabolite in cattle, together with the assessment that 
its concentration in the urine of treated animals is relatively high, on the one hand provides a way to describe the depletion 
and fate of prednisolone and may explain the limited urinary excretion of the parent compound in such species. On the other 
hand, it suggests a possible approach to detect illegal pharmacological treatments. Both perspectives need further 
investigation to make the fundamental metabolic pathways of prednisolone in bovines clear, and further metabolites are 
likely to be identified in the future to possibly be used as biomarkers for discriminating exogenous administration of the 
drug from alleged endogenous production under stress conditions. However, we believe that a first crucial step was 
accomplished towards the recognition of illegal growth-promoting prednisolone treatments of beef cattle in animal breeding 
that could modify the monitoring strategy of official controls, most likely shifting from the parent drug to its metabolites. 
Our data show that dihydroprednisolone is detected and measured in all treated animals, unlike prednisolone, which is 
detected only in a few cases and, notably, in concentrations largely below the threshold of 5 ppb, established by the Italian 
Ministry of Health. Therefore, all the studied samples are compliant with the current legislation, although they come from 
surely treated animals. It stems that new markers able to clearly detect illicit treatments are needed. 
 
 
 Figure 4.    Chromatographic profiles of three SRM transitions distinctive for 6β-hydroxyprednisolone and 20β-dihydroprednisone, 
respectively, from the urine sample collected 10 days after the first pharmacological administration of prednisolone acetate to a bullock. 
 Figure 5. Chromatographic profiles of the three SRM transitions distinctive for 20β-dihydroprednisolone. (Left) Blank urine spiked with 
20α- and 20β-dihydroprendisolone at the final concentration of 1 ng mL_1. (Centre) Urine sample from animal 28 D, collected at the 10th day 
of low-dosage treatment. (Right) Real urine sample collected from untreated animal 17 K. 
Table 3.    Prednisolone and 20β-dihydroprednisolone levels (ng mL   ) in urine samples from beef cattle treated with low dosages of 
prednisolone acetate to mimic a growth-promoting protocol. 
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